Hope

SANUWAVE Announces Record Q4 and FY2023 Revenue

Retrieved on: 
Friday, March 22, 2024
Growth, FY, Acceleration, Health, The Company, Human, News, Hope, Record, FDA, Beauty salon

EDEN PRAIRIE, MN, March 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months and fiscal year ended December 31, 2023.

Key Points: 
  • 79 UltraMIST® systems were sold in Q4 2023, up from 28 in Q1 2023, 49 in Q2 2023, and 55 in Q3 2023.
  • In addition, 19 systems were placed into RTO (rent to own) contracts in Q4 2023.
  • UltraMIST® consumables revenue increased by 21% to $3.6 million (51% of revenues) in Q4 2023, versus $3.0 million for the same quarter last year.
  • UltraMIST systems and consumables remained the primary revenue growth driver and represented in excess of 90% of SANUWAVE’s overall revenues in Q4 2023.

211 Impact Survey Uncovers Widespread Unmet Community Needs Nationwide

Retrieved on: 
Thursday, March 21, 2024
Head, Substance abuse, Trust, Social support, COVID-19, Mental, Mental health, Policy, Transport, Food, Hope, United Way, Insurance, Housing, Meal, Nursing

The survey results of nearly 16 million requests* and 19 million referrals* show housing, utilities, and food assistance remain the top needs of people seeking support nationwide.

Key Points: 
  • The survey results of nearly 16 million requests* and 19 million referrals* show housing, utilities, and food assistance remain the top needs of people seeking support nationwide.
  • Key findings from the 2023 211 Impact Survey:
    Housing assistance referrals continue to increase, with total referrals nearly double pre-pandemic numbers.
  • Nearly 95 percent of 211 leaders reported unmet needs related to housing, 61.6 percent related to utilities, and 52.2 percent related to transportation.
  • The annual 211 Impact Survey plays a central role in understanding the evolving needs of individuals, families, and communities.

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Retrieved on: 
Thursday, March 21, 2024
Organ transplantation, Kidney disease, University of Minnesota, Massachusetts General Hospital, Risk, Patient, Immunosuppression, Research, Kidney transplantation, University, Kidney, Hope, Tacrolimus, Doctor of Philosophy, MD, Person, Hospital, Heart, Immune system, Calcineurin, Division, CD40L, Dentistry

IRVINE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that tegoprubart, the company’s investigational anti-CD40L antibody, was used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human. The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man living with end-stage kidney disease.

Key Points: 
  • The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man living with end-stage kidney disease.
  • “Eledon has now participated in both heart and kidney xenotransplant procedures, further demonstrating tegoprubart’s broad potential in transplant.
  • Tegoprubart has been observed to be safe and well-tolerated in multiple studies and in multiple indications, including for the prevention of rejection following kidney transplantation.
  • In parallel, Eledon is running two global clinical studies evaluating tegoprubart for the prevention of organ rejection in persons receiving a de novo kidney transplant.

ETFS Capital Releases Letter to Fellow WisdomTree Stockholders

Retrieved on: 
Thursday, March 21, 2024
Bitcoin, Failure, Common stock, Letter, WisdomTree Investments, ETF, ALL, Sale, Hope, Disclosure, Decentralized finance, AUM, Management

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- ETFS Capital Limited (“ETFS Capital”), the largest combined owner of common stock, $0.01 par value (the “Common Stock”), and Series A Non-Voting Convertible Preferred Stock (the “Series A Preferred Stock”) of WisdomTree, Inc. (“WisdomTree” or the “Company”) (NYSE: WT), with ownership of approximately 10.2% of the outstanding Common Stock, which together with its Series A Preferred Stock would represent approximately 18.3% of the Company’s outstanding Common Stock on an as-converted basis, today released a letter to its fellow WisdomTree shareholders, responding to a public letter from WisdomTree board of director’s (the “Board”) to ETFS Capital’s Chairman, Mr. Graham Tuckwell.

Key Points: 
  • WisdomTree Prime is and always has been a complete folly in our opinion, and in crypto ETFs the Company continues to rank towards the bottom relative to peers.
  • Consequently, WisdomTree trades at a significant discount to its intrinsic value if it were a well-run pure-play ETF business.
  • In our February 20, 2024, letter to the Board, we acknowledged that individual members of the Board and stockholders (such as ETFS Capital) have divergent views about the best way forward to unlock value at WisdomTree.
  • Fellow stockholders, over the past three years, we have attempted to address operational and governance failures through proxy campaigns.

TLI Investigator Dr. Nicholas Jenzjowsky Receives NIH/NIAID Grant to Investigate the Neural Regulation of Asthma

Retrieved on: 
Wednesday, March 20, 2024
TLI, Asthma, Research, Hope, Doctor of Philosophy, Allergy, Neuron, Immunoglobulin E, Infection, Pharmaceutical industry

The grant will fund the innovative project "Asthmatic inflammation requires neuronal upregulation of B-cells," which commenced this month and will run until January 2025.

Key Points: 
  • The grant will fund the innovative project "Asthmatic inflammation requires neuronal upregulation of B-cells," which commenced this month and will run until January 2025.
  • This groundbreaking research aims to delve into the complexities of asthma and its symptoms, a major global health concern that requires a deeper understanding of its underlying mechanisms.
  • The innovative nature of this project underscores TLI's commitment to cutting-edge science and the potential impact of the research.
  • It aims to uncover potential drug targets and inform new strategies to mitigate the growing problem of allergic asthma.

AAFA Statement on EPA Cars Rule

Retrieved on: 
Wednesday, March 20, 2024
AAFA, Climate change, Season, Asthma, Light, Policy, Hope, Quality of life, EPA, Pollen, Air pollution, Weather, Renewable energy

Washington, D.C., March 20, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) applauds a new rule by the Environmental Protection Agency (EPA) that will drive America toward a future with zero vehicle emissions.

Key Points: 
  • Washington, D.C., March 20, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) applauds a new rule by the Environmental Protection Agency (EPA) that will drive America toward a future with zero vehicle emissions.
  • The EPA announced final national pollution standards for passenger cars, light-duty trucks, and medium-duty vehicles for model years 2027 through 2032 and beyond.
  • “Transportation-related emissions are a leading contributor to air pollution,” said Kenneth Mendez, president and CEO of AAFA.
  • By reducing emissions from cars and light trucks, the EPA’s new rule will improve the quality of life for the 27 million people in the United States with asthma.

Jonathan Roumie of “The Chosen” to be Catholic University’s 2024 Commencement Speaker

Retrieved on: 
Wednesday, March 20, 2024
Clergy, Law school, Pontifical university, WWII, Ethics, Trauma, Graduation, Green, Immaculate Conception, St. Michael's Church, Nature, National shrine, Television, Catholic higher education, Prejudice, Education, Life, CIU, Pontifical academy, Theology, Catholic Church, Persecution, Supreme court, Basilica, Jesuits, University, Research, Edmund the Martyr, Empire, Death, Rabbi, Student, Survivor, Meditation, Gospel, Book, Advertising, The, International Theological Commission, Eucharist, Abuse, Catholic University of America, Hope, Liturgical music, Our Sunday Visitor, Guggenheim Fellowship, Super Bowl, Music, Moxo, Hearing, Human, Commander, Nursing

Washington, D. C., March 20, 2024 (GLOBE NEWSWIRE) -- Award-winning actor Jonathan Roumie of “The Chosen,” will serve as the commencement speaker for The Catholic University of America’s 2024 graduation ceremony held on Saturday, May 11, 2024.

Key Points: 
  • Washington, D. C., March 20, 2024 (GLOBE NEWSWIRE) -- Award-winning actor Jonathan Roumie of “The Chosen,” will serve as the commencement speaker for The Catholic University of America’s 2024 graduation ceremony held on Saturday, May 11, 2024.
  • Roumie also starred in the 2023 movie, “Jesus Revolution.”
    In addition to his work as an actor, Roumie is actively involved with his Catholic faith.
  • Catholic media have recognized him as a leader of the faith, with Our Sunday Visitor naming Roumie to a list of Catholics of the Year in 2022.
  • The Commencement ceremony will be held on the steps of the Basilica of the National Shrine of the Immaculate Conception.

Mountain America Credit Union Partners with Operation Warm to Donate Shoes to Local Children

Retrieved on: 
Wednesday, March 20, 2024
Operation, Partnership, Shoe, Organization, Hope, Mountain America Credit Union

The shoes were distributed to children by representatives of OWCAP, Mountain America, and Operation Warm.

Key Points: 
  • The shoes were distributed to children by representatives of OWCAP, Mountain America, and Operation Warm.
  • Operation Warm is a national nonprofit dedicated to providing warmth, confidence, and hope for children in need—through the gift of coats and shoes.
  • Since 2019 Mountain America has donated 5,000 coats and 3,000 shoes through their partnership with Operation Warm.
  • “At Mountain America Credit Union, we believe in the power of collaboration to make a meaningful impact in our community,” shares Nathan Anderson, chief operating officer at Mountain America Credit Union.

Dr. Zeke Unveils Breakthrough Scoliosis Treatment, Transforming Lives in Austin, TX

Retrieved on: 
Wednesday, March 20, 2024
Health, Attention, Spine, Patient, Research, Hope, Quality of life, Scoliosis, Heart, Optimism, Rehabilitation, Medical device

Scoliosis, a condition characterized by an abnormal curvature of the spine, affects millions worldwide, impacting individuals of all ages.

Key Points: 
  • Scoliosis, a condition characterized by an abnormal curvature of the spine, affects millions worldwide, impacting individuals of all ages.
  • "We believe that every patient deserves the chance to live a life free from the constraints of scoliosis," says Dr. Zeke.
  • As a national leader in scoliosis treatment, Dr. Zeke's clinic has garnered widespread acclaim for its transformative results and compassionate approach.
  • For those suffering from scoliosis, Dr. Zeke's clinic offers a beacon of hope in their journey towards a pain-free and active life.

Sift Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024

Retrieved on: 
Tuesday, March 19, 2024
Editorial, Culture, Organization, MIC, Patent, Sieve, SAN, AI, Hope, Forrester Research, ITunes, Investment, Most, Fraud, Security, Machine learning, Publishing

SAN FRANCISCO, March 19, 2024 (GLOBE NEWSWIRE) -- Sift , the AI-powered fraud platform securing digital trust for leading global businesses, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024, coming in at No.

Key Points: 
  • SAN FRANCISCO, March 19, 2024 (GLOBE NEWSWIRE) -- Sift , the AI-powered fraud platform securing digital trust for leading global businesses, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024, coming in at No.
  • Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.
  • The World's Most Innovative Companies stands as Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year.
  • This event celebrates the Most Innovative Companies honorees and provides an inside look at cutting-edge business trends and what it takes to innovate in 2024.